Table 1 Outcomes, number of persons choosing the various strategies, and the pharmaceutical company’s drug development strategies
Outcome | 1 | 2 | 3 | 4 | 5 | 6 | 7 |
|---|---|---|---|---|---|---|---|
Number of persons | G | L | N-G-L-M1-m1 | M1 | m1-M2- m12 | M2 | m12 |
Person i | Safe behavior | Risky behavior | Disease contraction | Not buy drug 1 | Buy drug 1 | Not buy drug 2 | Buy drug 2 |
m1 | 0 | 0 | 0 | 0 | > 0 | > 0 | > 0 |
m12 | 0 | 0 | 0 | 0 | 0 | 0 | > 0 |
Company’s expected profit | 0 | 0 | 0 | −(1 − X1)d1 | Eq (2) | Eq (2) | Eq (2) |
Company | No drug development | Drug 1 development | Drug 2 development | ||||